Naseem J. Zojwalla

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

Targeting renal cell carcinoma with a HIF-2 antagonist

Wenfang Chen, Haley Hill, Alana Christie et al. · Nature · 2016 · 697 citations · Full text

Urology, Genitourinary Cancer, Renal Cell Carcinoma +4

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam et al. · Journal of Clinical Oncology · 2017 · 369 citations · Full text

Peripheral Edema, Tumor Biology, Conclusion Pt2385 +12

Hormone receptor status and survival in a population‐based cohort of patients with breast carcinoma

Victor R. Grann, Andrea B. Troxel, Naseem J. Zojwalla et al. · Cancer · 2005 · 230 citations

Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Kyriakos P. Papadopoulos, David S. Siegel, David H. Vesole et al. · Journal of Clinical Oncology · 2014 · 95 citations · Full text